CAFL
|
Hypertension 2
|
10000
15
20
2112
304
324
528
6
7.83
727
787
880
9.19
95
|
XTRA
|
Hypertension 3
|
10000
15
20
2112
304
3176
324
528
6
7.83
727
787
880
9.18
95
|
XTRA
|
Infections 2
|
1500
1600
2112
2170
428
440
5000
600
625
650
700
760
776
787
832
|
CAFL
|
Infections General Secondary
|
1500
1600
1865
2112
428
440
450
500
5000
600
625
650
660
666
690
700
760
776
832
|
XTRA
|
Kidney Stimulation
|
100
1016
112
1134
1153
120
125
146
1500
152
1550
1600
1864
20
2112
2222
240
2400
250
2720
28
334
40
440
4412
442
465
524
582
600
625
64
644
651
668
676
712
72
728
732
751
784
800
854
880
93
96
|
CAFL
|
Leukoderma Acquired
|
20
2112
440
444
600
650
727
787
880
|
XTRA
|
Lymph Drain Circulation
|
1.5
10
10.36
1000
10000
146
148
15
15.05
15.33
1865
20
20.5
2112
3.6
3176
324
428
440
444
465
5000
522
528
6.3
66
660
676
690
727.5
743
787
8
880
|
CAFL
|
Nerve Disorders and Neuropathy
|
10000
125
1550
1600
1800
20
2112
2170
2489
2720
440
600
625
650
660
72
727
787
802
880
95
|
XTRA
|
Nerve Disorders and Neuropathy
|
10000
125
1550
1600
1800
20
2112
2170
2489
2720
3
3176
440
600
625
650
660
7.83
72
727
787
802
880
95
|
CAFL
|
Parasites General 1
|
120
128
1550
1862
2112
422
4412
644
676
688
712
728
732
800
|
CAFL
|
Parasites General Comprehensive
|
112
120
125
128
152
1550
1864
20
2112
240
2400
2720
334
422
4412
442
465
5000
524
64
644
651
688
712
72
728
732
800
854
880
96
|
CAFL
|
Sexual Dysfunction Men
|
124
20
2008
2112
2127
465
600
625
650
666
690
72
727
73.95
787
802
880
9.39
|
CAFL
|
Stroke Follow Up
|
10000
125
1800
1865
20
203
2112
2720
3
428
522
600
625
650
72
727
787
880
95
|
CAFL
|
Vitiligo
|
20
2112
440
444
600
650
727
787
880
|